Pfizer Inc. (NYSE:PFE) reported that an experiment indicated its lung-cancer medicine Xalkori appreciably enhanced progression-free endurance for earlier treated patients with anaplastic lymphoma kinase-positive complex non-small cell lung cancer.
In August, Food and Drug Administration in US accepted Xalkori, also called as crizotinib, as a cure for ALK-positive advanced NSCLC patients. Pfizer also began marketing the capsules in Japan previous month.
The drug manufacturer reported that its Profile 1007 study evaluated Xalkori with the chemotherapy medicines pemetrexed and docetaxel.
Its competitors include Merck & Co., Inc. (NYSE:MRK) that surged 1.00% to $39.24 with the total traded volume of 2.43 million shares and Novartis AG (ADR) (NYSE:NVS) that moved up 2.39% to $55.30 with the total traded volume of 923,876.00 shares.
Other healthcare stocks with bullish trend include Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) up 5.65% to $9.91, Johnson & Johnson (NYSE:JNJ) up 0.63% to $66.72 and Boston Scientific Corporation (NYSE:BSX) up 1.99% to $5.89, whereas with bearish trend include CEL-SCI Corporation (NYSEAMEX:CVM) down -15.34% to $0.347, Dendreon Corporation (NASDAQ:DNDN) down -4.79% to $7.16 and Genetic Technologies Limited (ADR) (NASDAQ:GENE) down -3.29% to $4.11.
Pfizer Inc. (NYSE:PFE) after opening at $22.72 hit high price of $22.80 and then trading at $22.80 by surging 0.80% at 10:52AM EDT and on current session volume of 4.63 million shares is surprisingly lower than its average volume of 34.76 million shares.
The stock price volatility was 1.58% for a week and 1.47% for a month as well as price volatility’s Average True Range for 14 days was 0.35 and its beta remained 0.71.
The liquidity measure in recent quarter results of the company was recorded 2.02 as current ratio and on the other side the debt to equity ratio was 0.47 and long-term debt to equity ratio also remained 0.40. The Company had total cash at hand $23.99 billion and a book value per share as $11.11 in the most recent quarter.
PFE generated revenue of 66.33 billion in the following twelve months and earned $8.28 billion. The Company showed a positive 12.54% in the net profit margin and as well as in its operating margin which remained 18.39%. Company’s annual sales growth for the past five year was 6.87%.